ORA - Oxford University Research Archive

1 - 9 of 9

1

Journal article

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.

Walters, MJ, Wang, Y, Lai, N, et al.
2010-10-05

2

Conference

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease

Keshav, S, Johnson, D, Bekker, P, et al.
2009-05-05

3

Conference

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B

Ungashe, SB, Wei, Z, Rubas, W, et al.
2008-04-06

4

Conference

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease

Keshav, S, Petryka, R, Vanask, T, et al.
2007-09-05

5

Conference

Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease

Keshav, S, Ungashe, S, Zheng, W, et al.
2007-04-05

6

Journal article

Chemokines and myeloid cell recruitment.

Greaves, DR, Schall, TJ
2000-03-05

7

Journal article

Abduction of chemokine elements by herpesviruses

Dairaghi, DJ, Greaves, DR, Schall, TJ
1998-04-05

8

Journal article

CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells.

Greaves, DR, Wang, W, Dairaghi, DJ, et al.
1997-09-05

9

Journal article

A new class of membrane-bound chemokine with a CX3C motif.

Bazan, JF, Bacon, KB, Hardiman, G, et al.
1997-02-05

TO TOP